These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24109538)

  • 21. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
    Park JH; Kim TM; Keam B; Jeon YK; Lee SH; Kim DW; Chung DH; Kim YT; Kim YW; Heo DS
    Clin Lung Cancer; 2013 Jul; 14(4):383-9. PubMed ID: 23313171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
    Funakoshi Y; Takeuchi Y; Maeda H
    Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating
    Kuwata T; Yoneda K; Kobayashi K; Oyama R; Matumiya H; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Imanishi N; Kuroda K; Tanaka F
    Case Rep Oncol; 2016; 9(3):565-567. PubMed ID: 27790122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
    Takamochi K; Suzuki K; Sugimura H; Funai K; Mori H; Bashar AH; Kazui T
    Lung Cancer; 2007 Oct; 58(1):149-55. PubMed ID: 17548126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.
    Toda-Ishii M; Akaike K; Kurisaki-Arakawa A; Arakawa A; Mukaihara K; Suehara Y; Takagi T; Kaneko K; Yao T; Saito T
    Int J Clin Exp Pathol; 2015; 8(3):3270-8. PubMed ID: 26045851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.
    Singh N; Kulkarni P; Aggarwal AN; Mittal BR; Gupta N; Behera D; Gupta A
    Medicine (Baltimore); 2012 Jul; 91(4):179-194. PubMed ID: 22732948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    Kobayashi S; Boggon TJ; Dayaram T; Jänne PA; Kocher O; Meyerson M; Johnson BE; Eck MJ; Tenen DG; Halmos B
    N Engl J Med; 2005 Feb; 352(8):786-92. PubMed ID: 15728811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
    Shoji F; Yano T; Yoshino I; Mori D; Yamasaki F; Kohno H; Maehara Y
    Eur J Surg Oncol; 2008 Jan; 34(1):89-93. PubMed ID: 17449217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
    Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M
    Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
    Kataoka K; Osaka E; Shimizu T; Okamura Y; Yoshida Y; Tokuhashi Y
    Thorac Cancer; 2016 Nov; 7(6):676-680. PubMed ID: 27755795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Nishimatsu K; Minami S; Ihara S; Yasuoka H
    J Med Cases; 2021 Aug; 12(8):310-314. PubMed ID: 34434479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
    Hirano S; Sano K; Takeda Y; Ishii S; Naka G; Iikura M; Izumi S; Hojo M; Sugiyama H; Kobayashi N; Kudo K
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1501-6. PubMed ID: 23064060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
    Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
    J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
    Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib.
    Sato K; Takeyama Y; Yoshihara M; Kato T; Hashimoto H; Fukui Y; Gonda H; Suzuki R
    Case Rep Oncol; 2012 Sep; 5(3):546-53. PubMed ID: 23139670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
    Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
    Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N; Li H; Su F; Li J; Ma X; Gong P
    Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.